 Antiviral Agents
"Antiviral Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
| Descriptor ID |
D000998
|
| MeSH Number(s) |
D27.505.954.122.388
|
| Concept/Terms |
Antiviral Agents- Antiviral Agents
- Agents, Antiviral
- Antivirals
- Antiviral Drugs
- Drugs, Antiviral
|
Below are MeSH descriptors whose meaning is more general than "Antiviral Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiviral Agents".
This graph shows the total number of publications written about "Antiviral Agents" by people in this website by year, and whether "Antiviral Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 1 | 4 | | 1997 | 7 | 2 | 9 | | 1998 | 4 | 2 | 6 | | 1999 | 1 | 0 | 1 | | 2000 | 4 | 0 | 4 | | 2001 | 3 | 2 | 5 | | 2002 | 6 | 3 | 9 | | 2003 | 7 | 0 | 7 | | 2004 | 8 | 6 | 14 | | 2005 | 5 | 4 | 9 | | 2006 | 7 | 3 | 10 | | 2007 | 11 | 7 | 18 | | 2008 | 7 | 5 | 12 | | 2009 | 8 | 7 | 15 | | 2010 | 10 | 6 | 16 | | 2011 | 11 | 10 | 21 | | 2012 | 14 | 2 | 16 | | 2013 | 17 | 1 | 18 | | 2014 | 10 | 5 | 15 | | 2015 | 25 | 11 | 36 | | 2016 | 23 | 5 | 28 | | 2017 | 15 | 7 | 22 | | 2018 | 18 | 7 | 25 | | 2019 | 20 | 11 | 31 | | 2020 | 23 | 14 | 37 | | 2021 | 22 | 12 | 34 | | 2022 | 9 | 30 | 39 | | 2023 | 2 | 17 | 19 | | 2024 | 15 | 8 | 23 | | 2025 | 18 | 3 | 21 | | 2026 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
Hecht CJS, Parker RR. RK-33 inhibits the OC43 coronavirus and induces stress granules via DDX3X-independent mechanisms. RNA. 2026 Apr 16; 32(5):724-735.
-
Kim AY, Kang M, Umbleja T, Nunes EP, Marks KM, Luetkemeyer AF, Koebele C, Wimbish C, Fierer DS, Kliemann DA, Solomon SS, Kort J, Kiser JJ, Lauer GM, Chung RT, Sowah LA, Alston-Smith BL, Wyles DL, Naggie S. Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C. Clin Infect Dis. 2026 Feb 04; 81(6):1083-1090.
-
Ustianowski A, Levin MJ, De Wit S, Launay O, Veekmans B, Rampling T, Sullivan JG, Vishnepolsky M, Wijewardane P, Fawadleh Y, Zhang H, Li M, Wickramarachchi D, Sharbaugh A, Beavon R, Thissen J, Hirao L, Dzutseva V, Seegobin S, Streicher K, Kiazand A, Esser MT, Chang LJ, Perez JL, Cohen TS. Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study. Clin Drug Investig. 2026 Feb; 46(2):207-219.
-
Shah MM, Abedi GR, Lu S, Garcia-Knight M, Pineda-Ramirez J, Goldberg SA, Grijalva CG, Keipp Talbot H, Schmitz J, Lutrick K, Ellingson KD, Stockwell MS, Sano E, Nguyen HQ, Rao S, Asturias EJ, Suthar MS, Mellis AM, Deeks SG, Martin JN, Peluso MJ, Andino R, Rolfes MA, Kirking HL, Smith-Jeffcoat SE, Midgley CM, Hagen MB, Kelly JD. SARS-CoV-2 infectious shedding and rebound among adults with and without oral antiviral use: two case-ascertained prospective household studies. Lancet Microbe. 2026 Jan; 7(1):101227.
-
Sears JD, Popov KI, Sylvester PA, Dickmander R, Diaz J, Chang CK, Huff J, Sanders W, Saba NA, Sorensen M, Drobish AM, May NA, Namitz K, Fecko J, Yennawar NH, Morrison TE, Tropsha A, Heise MT, Moorman NJ. Novel computational pipeline to identify target sites for broad spectrum antiviral drugs. Antiviral Res. 2026 Jan; 245:106322.
-
Concannon K, Page R, Swayngim R, Ambardekar AV, Chiu CY, Schoeppler K, Sartain E. Low-Dose Valganciclovir for Primary Cytomegalovirus Prophylaxis After Heart Transplant: A 10-Year Experience. Clin Transplant. 2025 Dec; 39(12):e70408.
-
Adams K, Garg S, Tartof SY, Irving SA, DeSilva MB, Klein NP, Natarajan K, Dascomb K, Grannis SJ, Ong TC, Salas SB, Sy LS, Lewin B, Qian L, Naleway AL, Koppolu PD, McEvoy CE, Akinsete O, Essien I, Fireman B, Zerbo O, Jacobson KB, Timbol J, Neelam V, Reeves EL, Dickerson M, Ray C, Link-Gelles R, Mak J, Ball SW, O'Reilly M, Olsen SJ, Tenforde MW. Patterns in Prescribing and Dispensing Influenza Antivirals Among Adults With Influenza Presenting to Urgent Care and Emergency Department Settings: VISION Network, 2023-2024. Clin Infect Dis. 2025 Nov 06; 81(4):e172-e183.
-
Pasco R, Hayden FG, Meyers LA. Modeling Influenza Antiviral Strategies: Reducing Burden and Preventing Resistance. J Infect Dis. 2025 Oct 17; 232(Supplement_3):S299-S308.
-
Bassett HK, Rao S, Beck J, Brady PW, Jhaveri R, Joerger T, Liang D, Quinonez R, Shine A, Somers M, Lucas BP, Schroeder AR. Clinician Preferences for Oseltamivir Use in Children With Influenza in the Outpatient Setting. Pediatrics. 2025 Sep 01; 156(3).
-
Lewis NM, Harker EJ, Grant LB, Zhu Y, Grijalva CG, Chappell JD, Rhoads JP, Baughman A, Casey JD, Blair PW, Jones ID, Johnson CA, Lauring AS, Gaglani M, Ghamande S, Columbus C, Steingrub JS, Shapiro NI, Duggal A, Busse LW, Felzer J, Prekker ME, Peltan ID, Brown SM, Hager DN, Gong MN, Mohamed A, Exline MC, Khan A, Hough CL, Wilson JG, Mosier J, Qadir N, Chang SY, Ginde AA, Martinez A, Mohr NM, Mallow C, Harris ES, Johnson NJ, Srinivasan V, Gibbs KW, Kwon JH, Vaughn IA, Ramesh M, Safdar B, Goyal A, DeLamielleure LE, DeCuir J, Surie D, Dawood FS, Tenforde MW, Uyeki TM, Garg S, Ellington S, Self WH. Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study. Clin Infect Dis. 2025 Aug 01; 81(1):190-197.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|